A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 9, 2005, Pages 2269-2272

  Meyer, François ^a   Galan, Pilar ^c   Douville, Pierre ^b   Bairati, Isabelle ^a   Kegle, Pastelle ^a   Bertrais, Sandrine ^c   Czernichow, Sébastien ^c   Hercberg, Serge ^c  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BIOLOGICAL MARKER; CONNECTIVE TISSUE GROWTH FACTOR; IGFBP RELATED PROTEIN 3; SELENIUM; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG; VITAMIN; ZINC;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CONFIDENCE INTERVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZATION; VITAMIN SUPPLEMENTATION;

ANTIOXIDANTS; CASE-CONTROL STUDIES; CHEMOPREVENTION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; SOMATOMEDINS;

EID: 27744550673     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0303     Document Type: Article

References (24)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
2. Pollak M, Beamer W, Zhang JC. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 1999;17:383-90.
3. Shi R, Berkel HJ, Hu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001;85:991-6.
4. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
5. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-109.
6. Schaefer C, Friedman GD, Quesenberry CP, Orentreich N, Vogelman JH. IGF-I and prostate cancer. Science 1998;282:199a.
7. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004;22:3104-12.
8. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-65.
9. Lacey JV, Hsing AW, Fillmore CM, Hoffman S, Helzlsouer KJ, Comstock GW. Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. Cancer Epidemiol Biomarkers Prev 2001;10:1001-2.
10. Woodson K, Tangrea JA, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003;63:3991-4.
11. Janssen JAMJL, Wildhagen MF, Ito K, et al. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein -3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population -based screening with a 4-year interval. J Clin Endocrinol Metab 2004;89:4391-6.
12. Chen C, Lewis SK. Voigt L, et al. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005;103:76-84.
13. Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004;64:2335-42.
14. Meyer F, Galan P, Douville P, et al. Antioxidant vitamins and minerals supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 2005;116:182-6.
15. Stamey TA. Second Stanford conference on international standardization of prostate-specific antigen immunoassays. Urology 1995;45:173-84.
16. Crosby SR, Anderton CD, Westwood M, et al. Measurement of insulin-like growth factor-II in human plasma using a specific monoclonal antibody-based two-site immunoradiometric assay. J Endocrinol 1993;137:141-50.
17. Elmlinger MW, Kuhnel W, Weber MM, Ranke MB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 2004;42:654-64.
18. Yu H, Mistry J, Nicar MJ, et al. Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab Anal 1999;13:66-72.
19. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
20. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-7.
21. Chokkalingam AP, Pollak M, Fillmore CM, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001;10:421-7.
22. Oliver SE, Gunnel D, Donovan J, et al. Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer 2004;108:887-92.
23. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenberg RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993;76:1031-5.
24. Kanety H, Madjar Y, Dagan Y, et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer; correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993;77:229-33.